Table 2 Characteristics of the included studies
Study | Study Design | No. of Patients | CKD | Non-CKD | Mean Age (y) | Female Gender (%) | Follow-Up mean (range) (y) | Stage of CKD | Method to identify CKD | Outcome Measures | |
|---|---|---|---|---|---|---|---|---|---|---|---|
CKD non-CKD | |||||||||||
McCleery 2010 | MR | 59,288 | 3916 | 55,372 | NC | NC | 58.9 | NC | Stage 1–5, including dialysis and transplant | ICD | Infection, revision; |
Miric 2013 | MR | 36,882 | 2686 | 34,196 | 73 | 67 | 62.4 | 2.1 (0–5) | Stage 3 (69 %), stage 4 (3 %), stage 5 (5.5 %), unspecified stage (22 %), including transplant | ICD | Infection, revision, PE, DVT, mortality, re-admission; |
Ponnusamy 2015 | MR | 4,182,887 | 1683 | 4,181,204 | 66.7 | 66.8 | 63.8 | NC | Stage 5, with dialysis | ICD | Infection, mortality, transfusion; |
Lizaur-Utrilla 2016 | MR | 45 | 15 | 30 | 69.3 | 70.1 | 53.3 | 3.4 (2–6) | Stage 5, including dialysis and transplant | Using diagnostic and surgical codes on the departmental arthroplasty database | Infection, transfusion; |
Kuo 2016 | MR | 615 | 205 | 410 | 72.1 | 71.0 | 27.3 | 2.7 (2-4.8) | Stage 2–5 (eGFR < 60 mL/min/1.73 m2) | Calculating eGFR | LOS, transfusion; |
Kuo 2017 | MR | 13,844 | 1459 | 12,385 | 71.6 | 70.3 | 76.8 | 2 | Stage 1–5 | ICD | Infection, PE, DVT, mortality, re-admission; |
Bedard 2018 | MR | 35,894 | 4551 | 31,343 | NC | NC | 63.7 | 2 | Stage 1–5 | ICD | Revision; |